Lindahl acted as legal advisor to Corline Biomedical
Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.
Lindahl's team consisted of Hugo Norlén and Erika Svensson.
Corline's press release (in Swedish) is available here.
Do you want to know more? Contact:
Hugo Norlén
Partner | AdvokatErika Svensson
Partner | AdvokatCarousel items
-
Cases and transactions
6/23/2026
Lindahl acts as legal adviser to Medivir in a private placement of approximately 140 MSEK
Lindahl acted as legal adviser to Medivir in connection with an oversubscribed private placement of SEK 140 million for the clinical development of the drug candidate MIV-711.
-
Knowledge
6/15/2026
Properly prepared — contract law in the new security landscape
Preparedness laws such as the Rationing Act and the Requisition Act can alter your contracts from one day to the next. Lindahl cuts through the terminology in the new security landscape.
-
News articles
6/11/2026
Lindahl recognised in Legal 500 Green Ambassadors 2026
Johanna Lundgren and Izabell Zaza recognised in Legal 500 Green Ambassadors Europe 2026, highlighting Lindahl’s expertise in sustainable business, energy and environmental law.
-
Portraits
6/2/2026
Björn on M&A at Lindahl: "No two deals are alike"
Björn Andersson on M&A at Lindahl: how each transaction brings new challenges – and why no two deals are alike. Read about his experience and approach.
-
Read more news and insights?
